Skip to main content
Smart Investors Daily
GH

OTC · GHSI

Guardion Health Sciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.25

Up+$0.03 (+0.93%)

Updated Aug 25, 2026, 11:03 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
4.17M
P/E ratio
26.14
Dividend yield
0.00%
52-week range
— – —
Volume
664
Avg. volume
32.63K

Price performance

GHSI price history

1M range · 0 trading sessions · Daily adjusted prices

GHSI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest GHSI news

The latest Smart Investors Daily articles mentioning GHSI.

GHSI research

Overview

Company profile and research snapshot.

Company profile

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$0.01
Implied upside
Analysts
7
GHSI recent ratings
DateFirmRatingTarget
Feb 2, 2024Maxim GroupHold
Jul 18, 2022Ascendiant CapitalBuy
Mar 8, 2022Maxim GroupBuy
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Aug 13, 2024

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

Guardion Health Sciences announced its financial results for the three and six months ended June 30, 2024. The company completed the sale of its Viactiv brand and business, and its stockholders approved a plan of liquidation and dissolution. The company is reviewing alternative transaction proposals and expects to make a decision on cash distributions to stockholders in the coming quarter.

GlobeNewswire Inc. · May 31, 2024

Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution

HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that today it closed on its Definitive Agreement to sell its Viactiv business to Doctor’s Best Inc. for gross cash consideration of $17,200,000. The Company received net cash proceeds of $16,250,000 at closing, with another $225,000 retained in a third-party escrow account with U.S. Bank, NA, to be released in accordance with the terms of the transaction documents.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.